Regeneron Pharmaceuticals' Change in Receivables fell 79.35% to $80.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$431.5 million, marking a year-over-year decrease of 183.16%. This contributed to the annual value of $554.0 million for FY2024, which is 63.52% up from last year.
According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Change in Receivables is $80.3 million, which was up 184.75% from $28.2 million recorded in Q2 2025.
In the past 5 years, Regeneron Pharmaceuticals' Change in Receivables ranged from a high of $2.8 billion in Q2 2021 and a low of -$1.5 billion during Q3 2021.
Over the past 3 years, Regeneron Pharmaceuticals' median Change in Receivables value was $80.3 million (recorded in 2025), while the average stood at $31.2 million.
As far as peak fluctuations go, Regeneron Pharmaceuticals' Change in Receivables tumbled by 2,154.03% in 2022, and later skyrocketed by 18,200.00% in 2024.
Regeneron Pharmaceuticals' Change in Receivables (Quarterly) stood at $584.5 million in 2021, then tumbled by 137.57% to -$219.6 million in 2022, then surged by 137.66% to $82.7 million in 2023, then skyrocketed by 42.44% to $117.8 million in 2024, then slumped by 79.35% to $80.3 million in 2025.
Its last three reported values are $80.3 million in Q3 2025, $28.2 million for Q2 2025, and -$657.8 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value